CTRI/2017/11/010531CompletedPhase 4
A retrospective, observational, real-world, safety and performance evaluation of DES and BMS for coronary artery lesions.
Meril Life Sciences Pvt Ltd0 sites750 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Enrollment
- 750
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Pms
Eligibility Criteria
Inclusion Criteria
- •1. Patients who have been treated with OSUM• and/or Metafor•.
- •2. Patients who are contactable, willing to participate will be taken into the study by signing voluntary informed consent form.
Exclusion Criteria
- •1. There are no exclusion criteria for this study.
Investigators
Similar Trials
Suspended
Not Applicable
Study to assess safety of Ayurvedic medicine in treatment of chronic illness.CTRI/2018/04/012912Rasayani Cancer Clinics Pune
Active, not recruiting
Phase 1
A research study to collect long term safety information from subjects who have received study treatment from a qualifying lenabasum Corbus trial.Dermatomyositis (DM) is a rare and serious autoimmune disease.An overactive immune response causes chronic inflammation,which results in growth of scar tissue in the skin,muscles,and many internal organs.Cystic Fibrosis (CF) is a genetic disorder which results in thick mucus formation on the airways leading to increased lung infections,fibrosis of the lungs and digestive tract and abnormal immune functionMedDRA version: 20.0Level: PTClassification code 10012503Term: DermatomyositisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 20.0Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-001762-11-HUCorbus Pharmaceuticals, Inc.100
Active, not recruiting
Phase 1
A research study to collect long term safety information from subjects who have received study treatment from a qualifying lenabasum Corbus trial.EUCTR2020-001762-11-GBCorbus Pharmaceuticals, Inc.100
Active, not recruiting
Phase 1
A research study to collect long term safety information from subjects who have received study treatment from a qualifying lenabasum Corbus trial.Dermatomyositis (DM) is a rare and serious autoimmune disease.An overactive immune response causes chronic inflammation,which results in growth of scar tissue in the skin,muscles,and many internal organs.Cystic Fibrosis (CF) is a genetic disorder which results in thick mucus formation on the airways leading to increased lung infections,fibrosis of the lungs and digestive tract and abnormal immune functionMedDRA version: 20.0Level: PTClassification code 10012503Term: DermatomyositisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 20.0Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-001762-11-SECorbus Pharmaceuticals, Inc.100
Active, not recruiting
Phase 1
A research study to collect long term safety information from subjects who have received study treatment from a qualifying lenabasum Corbus trial.Dermatomyositis (DM) is a rare and serious autoimmune disease.An overactive immune response causes chronic inflammation,which results in growth of scar tissue in the skin,muscles,and many internal organs.Cystic Fibrosis (CF) is a genetic disorder which results in thick mucus formation on the airways leading to increased lung infections,fibrosis of the lungs and digestive tract and abnormal immune functionMedDRA version: 20.0Level: PTClassification code 10012503Term: DermatomyositisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 20.0Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-001762-11-DECorbus Pharmaceuticals, Inc.100